Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2003, p. 4031-4037, Vol. 41, No. 9
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.9.4031-4037.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Division of Infectious Diseases,1 Division of Clinical Bacteriology, Department of Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,4 Department of Communicable Disease Control and Prevention, Karolinska Hospital,2 Department of Molecular Epidemiology and Biotechnology, Swedish Institute for Infectious Disease Control, Stockholm, Sweden3
Received 16 July 2002/ Returned for modification 2 December 2002/ Accepted 13 June 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Clusters of nosocomial cases of CDAD have been attributed to transmission of C. difficile between patients but also indirectly through the hands of health care workers or via contaminated surfaces or fomites (10, 15, 19). Furthermore, some strains may be more transmissible and also more virulent than others and thus be associated with higher attack rates and a high local incidence of CDAD (12, 13, 21). Also, antibiotic treatment policies and infection control efforts such as hand hygiene and isolation practices may differ not only between hospitals and wards but also between time periods. These factors influence the rate of selection and nosocomial transmission of C. difficile and thus the local incidence of CDAD. Such factors might also explain reported outbreaks of CDAD even though molecular typing of isolates did not support nosocomial transmission of a particular C. difficile strain (11, 14, 20, 30).
The aim of the present study was to prospectively investigate the molecular epidemiology of CDAD at a university hospital during a stable endemic situation by PCR-ribotyping of C. difficile isolates from consecutive patients with C. difficile infection.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Patients were selected for the study by laboratory criteria (see below). Generally, a fecal sample for C. difficile diagnosis was sent to the laboratory within 3 days of onset of diarrhea. Date and duration of hospitalizations, date of samplings, and transfers of patients between wards were registered. The study was approved by the ethics committee of the Karolinska Institute (Huddinge, Sweden).
Definitions.
Diarrhea was defined as
3 loose stools per day for at least 2 days. CDAD was defined as diarrhea in a patient with a stool culture positive for C. difficile and/or fecal cytotoxin B (15). Hospital-associated CDAD was defined as episodes with onset after more than 72 h of hospitalization or present on admission in patients who had been hospitalized within the previous 2 months. Community-associated cases were defined as episodes occurring in patients within 72 h after admission but without a history of recent hospitalization, essentially as defined also by others (15, 19, 20). Patients who were hospitalized on the same ward within 2 months and from whom C. difficile of identical PCR ribotypes were isolated were presumed to reflect nosocomial acquisition of the organism (30). The first patient in each cluster was considered the index case, and the remaining ones were considered nosocomially acquired cases. Contact cases were defined as those hospitalized concomitantly in the same or an adjacent room as an index case.
Cytotoxin B detection and isolation of C. difficile. CDAD was diagnosed by examining feces for the presence of cytotoxin B by a McCoy cell assay in conjunction with a toxin/antitoxin kit (TechLab, Blacksburg, Va.). C. difficile was isolated as colonies of typical appearance on cycloserine-cefoxitin fructose agar supplemented with sodium taurocholate (6). The colonies were tested for toxin B production by the same McCoy assay. A fecal sample positive for C. difficile by culture and/or positive for cytotoxin B was considered positive.
PCR-ribotyping. All C. difficile isolates were subject to PCR-ribotyping. Cell pellets from overnight cultures of C. difficile were boiled in 5% Chelex, and PCR amplification of DNA between the genes encoding the 16S and 23S rRNAs was performed with Ready-to-Go PCR tubes (Amersham Biosciences) with the primer pairs and conditions described by Stubbs et al. (21) with minor modifications. The primers used were 5'-CTGGGGTGAAGTCGTAACAAGG-3' and 5'-GCGCCCTTTGTAGCTTGACC-3'. After an initial denaturation at 94°C for 5 min, the PCR conditions were 94°C for 60 s, 55°C for 60 s, and 72°C for 60 s, repeated for 30 cycles on a PTC-200 (MJ Research Inc.). After the final cycle, samples were heated for 72°C for 7 min and cooled to 4°C.
PCR products were separated on precast polyacrylamide gels (GeneGel Excel 12.5/24; Amersham Biosciences) and visualized by silver staining. In addition to the clinical isolates, the serogroup reference strains CCUG 37766 to 37787, corresponding to serogroups C, A2, A3, A4, A5, A6, A7, A8, A9, A10, S1, S3, S4, A, B, D, F, G, H, I, K, and X, respectively, were analyzed. Two reference strains (CCUG 37766 [serogroup C] and CCUG 37779 [serogroup A]) were included on each gel,and a 100-bp DNA ladder was run in every fifth lane. The use of polyacrylamide gels and silver staining resulted in higher resolution (Fig. 1) and thus higher discrimination than the standard agarose gels and ethidium bromide staining used by Stubbs et al. (21) (data not shown). For this reason, we used our own PCR ribotype numbers and prefixes (Sweden).
|
Statistical methods. The Mann-Whitney U test was used to compare ages in subsets of study patients, and the chi square test was used to evaluate differences in characteristics among patient subgroups. JMP software (SAS Institute, Cary, N.C.) was used for all statistical calculations.
| RESULTS |
|---|
|
|
|---|
Of the 227 cases, 164 (72%) were classified as hospital and 63 (28%) as community associated, although 122 patients (54%) had onset of diarrhea during their hospital stay, and 105 (46%) fell ill at home (Fig. 2). The median age of these 100 males and 127 females was 63 years (range, 1 to 95 years), and 203 patients (89%) had received antibiotics within 2 months prior to the onset of diarrhea. The subset of study patients did not differ from the total patient population with regard to age (median, 61.5 years; range, 1 to 95 years, P = 0.7), gender (135 males and 169 females, P = 0.9), or proportion of hospital-associated cases (214, 70%) versus community-associated cases (90, 30%) (P = 0.7).
|
Department-specific incidence of C. difficile infection. The patients were distributed among 17 of the 20 hospital departments (85%). Seven of these (nephrology, hematology, organ transplantation, infectious diseases, pediatrics, geriatrics, and gastroenterology) contributed 80% of the cases. These departments accounted for approximately 40% of the hospital beds. Their incidences of CDAD were 37.1, 30.2, 21.1, 18.3, 14.6, 13.9, and 4.6 cases/1,000 admissions, respectively, during the study period.
Patient contacts. Fecal samples from 59 patient contacts to 21 arbitrarily selected index patients were analyzed for C. difficile. The median age of the contacts, 24 males and 35 females, was 74 years (range, 30 to 92 years). Of the 59 patient contacts studied, seven (12%) ward mates to 5 of 21 index patients (24%) were positive for C. difficile by culture and/or fecal detection of cytotoxin B. Three of these seven patient contacts subsequently developed diarrhea.
PCR-ribotypes of C. difficile and their epidemiology. Of the 382 fecal samples culture positive for C. difficile, 198 (52%) were also positive for cytotoxin B, 119 (31%) only by isolation of toxigenic strains, and 65 (17%) yielded isolates negative for toxin B. Of the initial samples from each patient, 45 (20%) yielded C. difficile strains that did not produce toxin B in vitro.
All 382 isolates available were typeable by PCR-ribotyping. Among the 227 initial patient isolates, 70 different PCR-ribotypes were distinguished. Three of these, s20, s21, and s21b, whose ribotype was identical to that of the serogroup G, H, and A8 type strains accounted for 31% of the isolates (Table 1). Ten PCR-ribotypes were represented by more than five patients each, and 22 types were represented by two to five patients each, whereas 39 PCR-ribotypes were sporadic, i.e., found in only one patient each. Eight of 10 PCR-ribotype s3 strains (80%), five of five ribotype s32 strains (100%), and three of three ribotype s5 strains (100%) did not produce toxin B in vitro.
|
The distribution of the 10 most frequent PCR-ribotypes among departments, wards/linked wards, and over time is shown in Tables 2, 3, and 4. There was only minor apparent clustering of cases due to the same ribotype in space (Tables 2 and 3) and in time (Table 4). Among the isolates from 164 CDAD cases classified as hospital associated, 27 PCR-ribotypes occurred in more than one patient. Of the 138 patients having shared PCR-ribotypes, 56 occurred in 24 clusters of only two to three patients each and cared for in the same ward or two linked wards within the same 2-month period. Regarding the first CDAD patient of each pair or triplet as the index case transmitting his/her C. difficile strain to the other patient(s), an estimated 20% (32 of 164) of hospital-associated CDAD cases or 14% (32 of 227) of all CDAD cases reflected nosocomial acquisition of the strain (Fig. 2). Assuming that a ward served as a potential reservoir of a C. difficile ribotype not only for 2 months but during the whole 12 months of the study period, due to asymptomatic carriage among patients plus spores present in the rooms, the rate of nosocomial acquisition of the strain was estimated to 32% in hospital-associated cases and 23% in all cases. Notably, 77 of 304 (25%) patients were excluded from the analysis due to missing bacterial isolates for PCR-ribotyping.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The incidence of CDAD at Huddinge University Hospital has remained rather stable during the last 5 years, approximately 300 cases annually, corresponding to 7 cases per 1,000 admissions. This rate is in the lower range compared to the incidences of 1 to 30 cases per 1,000 admissions reported from many hospitals (1, 15, 18, 19, 24). The incidence of C. difficile infection was highest in the nephrology and hematology units (37 and 30 cases/1,000 admissions, respectively), as found also by others (17, 23, 28). Factors such as infection control procedures and antibiotic treatment policies may explain the differences in CDAD incidence between hospitals and changes over time within individual hospitals and wards.
A wide range of phenotypic and genotypic methods have been used to analyze the relatedness of C. difficile isolates in nosocomial outbreaks (3, 5, 8, 21, 25, 30). PCR-ribotyping is a discriminatory, reproducible, and relatively rapid technique that provides many advantages over other methods (3, 5, 8, 21). It was recently reported that although serotype G strains are nontypeable by pulsed-field gel electrophoresis, the discriminatory power of that technique was somewhat higher than that of PCR-ribotyping, partly because serogroup H and A8 isolates had the same PCR-ribotype pattern (3). However, by using polyacrylamide gels, we were able to clearly discriminate the serotype H and A8 type strains, obtaining the closely related PCR-ribotypes s21 and s21b (Fig. 1). In our study, polyacrylamide gels and silver staining revealed many weaker bands and thus provided additional PCR-ribotypes and improved discriminatory power compared to agarose gels and ethidium bromide staining of DNA.
In the present 1-year study, 70 different PCR-ribotypes of C. difficile were identified among 382 isolates from 227 patients. The cases and ribotypes were rather evenly distributed over the year, and the occurrence of PCR-ribotypes among cases defined as hospital associated and community associated was the same for several major PCR-ribotypes, indicating that these strains were often brought into the hospital by the patients. However, three PCR-ribotypes, s12, s16, and s25b, were unique to CDAD cases classified as hospital associated. No major clustering of any ribotype was found either by ward or in time, not even among the 10 most common ribotypes represented by more than five patients each. Instead, many apparent clusters comprising only two to three patients each were observed.
Seventy-two percent of the CDAD cases were primarily classified as hospital associated. Nosocomial acquisition of C. difficile was also assumed in cases sharing C. difficile of the same ribotype and admitted to the same ward within 2 months, suggesting hospital acquisition of the infecting strain for only 20% of nosocomial and 14% of all CDAD cases. Thus, a majority of the CDAD patients were apparently infected by endogenous rather than endemic ward strains, even among hospital-associated cases. It must be stressed, however, that 25% of the patients with C. difficile infection were excluded from the analysis because bacterial isolates were not available for PCR-ribotyping. The estimated rate of nosocomial acquisition could therefore be underestimated.
The prevention of C. difficile has been a main concern for our hospital infection control team for many years. Control measures that are continuously taught among the staff include isolation of patients with suspected infectious diarrhea in a single room, strict general barrier nursing, and specific cleaning routines whenever C. difficile is diagnosed. Our results support the notion that these efforts have been of value in minimizing the acquisition of C. difficile within the hospital. In recent years, a comprehensive infection control program has been launched to further reduce nosocomial infections due to C. difficile and antibiotic-resistant bacteria at Huddinge University Hospital.
Five of the 70 PCR-ribotypes, s3, s20, s21, s21b, and s22, accounted for as many as 40% of the C. difficile isolates. Ribotypes s3 and s22 were common at Huddinge University Hospital, whereas ribotypes s20, s21, and s21b were also common among hospitalized community-associated cases. Earlier studies indicated that certain serotypes of C. difficile might be more virulent than others (12). Whether the most common PCR-ribotypes are more transmissible or more virulent, contributing to their high overall incidence among our patients, has yet to be demonstrated. Studies are in progress to characterize the isolates from the dominant ribotypes found in our study more thoroughly with regard to toxin production, germination, and sporulation and also correlate such bacterial properties with the severity of clinical symptoms of the patients and with relapse risk.
Of more than 2,000 C. difficile isolates analyzed by PCR-ribotyping in the United Kingdom, one particular ribotype, denoted type 1, has shown a dramatic dominance in hospital settings, 55% of isolates compared to 7.5% among community isolates (21). No such dominant clone was observed in our material. The three most common PCR ribotypes s20, s21, and s21b, clustered together with the serogroup G, H, and A8 reference strains, respectively (Fig. 1). The banding pattern of s21b showed a pattern related to but different from that of s21 (Fig. 1), indicating a clonal relationship between these two. However, a preliminary genomic analysis of their surface layer proteins revealed significant differences between the respective type strains, CCUG 37784 (serogroup H) and CCUG 37773 (serogroup A8) (16). Thus, interpreting clonal relationships between bacterial strains on the results of only one typing method may not be sufficient. PCR ribotype s3 clustered together with CCUG 37781, belonging to serogroup D. This type strain is toxin A and B negative, and analysis of eight clinical isolates from this group showed that these were also toxin negative. Furthermore, all three strains from group s5 grouped together with type strain CCUG 37786 of serogroup K, a strain also noted to be toxin negative. The reason for the symptoms in these patients is unknown, but the presence of toxin-negative C. difficile in some patients may reflect a carrier state without a causal relationship to current diarrheal disease (22, 28) or that such strains carry unknown virulence factors.
In 79% of patients from whom two or more consecutive C. difficile isolates were available for PCR-ribotyping, the repeat isolate(s) was of the same ribotype as the initial one, indicating a low overall rate of reinfection. This is in agreement with several other reports (2, 27) and again apparently reflected successful infection control in our hospital, although the possibility of occasional reinfection with the same strain could not be ruled out. The fact that only 5% of the isolates were of a new ribotype in repeated fecal specimens collected within 30 days after the initial one also suggested that a single patient was rarely infected with multiple C. difficile strains, as reported also by others (2, 27).
Carriage of C. difficile in contacts to patients with CDAD is not uncommon (7, 10, 15, 19). Among 59 such contacts in the present study, 12% were positive for C. difficile by culture and/or fecal detection of cytotoxin B. This carriage rate is relatively low, considering that CDAD patients were present in the same ward, again supporting only a low level of transmission of C. difficile in the hospital. Since none of these isolates were available for PCR-ribotyping, possible nosocomial acquisition could not be studied.
In conclusion, 70 distinct PCR-ribotypes of C. difficile were found at Huddinge University Hospital during this prospective 1-year study. Ten ribotypes were dominant, although not markedly clustered in specific wards or in time, and the dominant types were equally common in CDAD cases classified as community associated and hospital associated. These observations indicated that nosocomial transmission of C. difficile was not a major problem during the study period. Our results indicate that CDAD in most patients was due to endogenous rather than hospital strains of C. difficile, even in cases classified as hospital associated. The CDAD incidence in a hospital is an indicator of implementation of hygienic routines and antibiotic policy and should be monitored continuously. Well-conceived and functioning infection control programs and antibiotic guidelines are important to keep CDAD rates at a minimum.
| ACKNOWLEDGMENTS |
|---|
We thank Annika Lundberg, Maj-Britt Olofsson, and Ingela Persson for expert technical assistance.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|